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Newly emerging viruses often circulate as a heterogeneous swarm in wild animal reservoirs prior to their
emergence in humans, and their antigenic identities are often unknown until an outbreak situation. The newly
emerging severe acute respiratory syndrome coronavirus (SARS-CoV) and reemerging influenza virus cause
disproportionate disease in the aged, who are also notoriously difficult to successfully vaccinate, likely due to
immunosenescence. To protect against future emerging strains, vaccine platforms should induce broad cross-
reactive immunity that is sufficient to protect from homologous and heterologous challenge in all ages. From
initial studies, we hypothesized that attenuated Venezuelan equine encephalitis virus (VEE) replicon particle
(VRP) vaccine glycoproteins mediated vaccine failure in the aged. We then compared the efficacies of vaccines
bearing attenuated (VRP3014) or wild-type VEE glycoproteins (VRP3000) in young and aged mice within novel
models of severe SARS-CoV pathogenesis. Aged animals receiving VRP3000-based vaccines were protected from
SARS-CoV disease, while animals receiving the VRP3014-based vaccines were not. The superior protection for
the aged observed with VRP3000-based vaccines was confirmed in a lethal influenza virus challenge model.
While the VRP3000 vaccine’s immune responses in the aged were sufficient to protect against lethal homologous
and heterologous challenge, our data suggest that innate defects within the VRP3014 platform mediate vaccine
failure. Exploration into the mechanism(s) of successful vaccination in the immunosenescent should aid in the
development of successful vaccine strategies for other viral diseases disproportionately affecting the elderly,
like West Nile virus, influenza virus, norovirus, or other emerging viruses of the future.
Newly emerging and reemerging viruses often circulate as a
heterogeneous swarm in wild animal reservoirs prior to their
emergence into the human population, and thus their antigenic
identities are often unknown until outbreak situations. Al-
though design of a vaccine that is protective against both con-
temporary and future emergent strains can be challenging, this
conundrum may in part be deflected through the development
vaccines that induce broad cross-reactive immunity, increasing
the likelihood of the protection from future emergent strains.
The newly emerging severe acute respiratory syndrome coro-
navirus (SARS-CoV) and the reemerging influenza virus ex-
emplify the many difficulties associated with effective vaccine
design for emerging pathogens. SARS-CoV emerged suddenly
in Guangdong Province in China in 2002 and reemerged in
2004, causing over 8,000 cases and greater than 700 deaths in
29 countries throughout the world (42). Recently, zoonotic
ancestors to the epidemic strain (SARS Urbani) have been
found in the putative animal reservoir, the Chinese horseshoe
bat, as well as in other exotic species commonly sold for food,
like raccoons, dogs, and palm civets (33). SARS-CoV disease is
characterized by an atypical pneumonia, in which approxi-
mately 20% of cases progressed to a particularly devastating
and clinically challenging end-stage disease, acute respiratory
distress syndrome (ARDS), requiring admission to intensive
care and mechanical ventilation (12, 34, 36, 45, 46). SARS-
CoV disease severity was directly associated with increasing
age, as mortality rates in people over the age of 65 exceeded
50% (16, 29). Currently, a vaccine is not available for SARS-
CoV. Similar to SARS-CoV, influenza virus causes dispropor-
tionate disease in the elderly; 90% of influenza-related deaths
in the United States (36,000/year) occur in people over the
age of 65 (41, 61). Although a seasonal influenza vaccine is
available, its efficacy is diminished in the most vulnerable aged
populations (17 to 53% effectiveness in the elderly, 70 to 90%
effectiveness in young adults) (25). Further complicating influ-
enza vaccine development are the phenomena of antigenic
drift and the antigenic shift most recently seen by the rapid and
unexpected emergence of pandemic H1N1 influenza virus in
2009, in which the previous 30 years of seasonal influenza
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vaccines afforded little protection against the newly emerged
pandemic strain (30). Lastly, two of the recently emerged in-
fluenza viruses, H5N1 and H1N1, caused a severe ARDS-like
disease similar to the severe cases of SARS-CoV (40, 70).
Given the global public health impacts of both SARS-CoV and
influenza virus, the development of vaccine platforms that in-
duce broadly cross-reactive immune responses in all age
groups is highly desirable.
The successful vaccination of elderly populations is a difficult
and unpredictable task due to deficiencies in the immune sys-
tem that develop with aging (9, 10, 19, 21, 25–27, 31, 44, 62, 63).
Immunosenescence, the gradual deterioration of the immune
system that occurs gradually with age, affects the innate and
adaptive immune compartments, contributing to decreased
vaccine efficacy in the aged (19, 21, 24–26, 31, 39, 62, 64). For
example, defects in antigen presentation, T cell activation, and
cytokine secretion affect the generation of effective adaptive
immune system helper cells (T helper or Th cells) and effector
cells (B cells and cytotoxic T cells), resulting in diminished
vaccine efficacy(19, 20, 24–26, 31, 39, 62, 64). Although both
SARS-CoV and influenza virus cause more severe disease in
the aged, few vaccine studies for SARS-CoV and influenza
virus have been performed in aged mouse models and even
fewer have been evaluated through heterologous virus chal-
lenge, which mimics vaccine challenge by divergent newly
emerging strains (3, 6, 15, 32, 66). Venezuelan equine enceph-
alitis virus (VEE) replicon particle (VRP) vaccines have re-
cently been clinically proven to be safe, replication-incompe-
tent vaccine vectors capable of inducing mucosal immunity
from a peripheral route of inoculation (8, 37, 60). To create a
VRP, the region of the genome encoding the viral glycopro-
teins is replaced with a transgene of interest, and to “package”
this chimeric RNA, VEE glycoproteins are provided in trans.
To date, VRP vaccines for human use and our previous SARS-
CoV vaccine studies have employed attenuated “traditional”
VEE coat proteins from the attenuated VEE 3014 strain
(VRP3014). The rationale for using attenuated glycoproteins
was to ensure there were several mechanisms of attenuation
within the vaccine vector, thereby enhancing safety. Compared
to wild-type VEE 3000, the VEE 3014 strain differs by only 3
amino acids within the viral glycoproteins, which have been
demonstrated to completely abrogate virus-induced mortality
through alteration of in vivo cell targeting (7, 38). In 2003,
Deming et al. demonstrated that vaccination with VRP assem-
bled with VEE 3014 strain coat proteins expressing SARS
Urbani S (VRP-S) provided complete protection from virus
replication in young mice but limited protection in aged mice
after heterologous challenge (icGD03-S), and protection was
coincident with the development of neutralizing antibodies
(15). Since the SARS-CoV replication models lack notable
morbidity and mortality, all earlier studies were unable to
assess protection from severe disease/death, and those inves-
tigators could only speculate that diminishing virus replication
might result in reduced disease severity (15, 50, 59).
Using divergent SARS-CoV strains rMA15 and rMA15
GD03-S, we developed two novel BALB/c mouse models of
SARS-CoV pathogenesis with age-dependent morbidity/mor-
tality and pathological findings of acute ARDS similar to those
noted in fatal human infections. Within these models of SARS-
CoV pathogenesis, we demonstrated that multiple antigeni-
cally divergent VRP3014-based VRP vaccines failed to protect
against replication, disease, and mortality following lethal ho-
mologous and heterologous SARS-CoV challenge in aged
mice. Given the failure of VRP3014-based vaccines in the aged,
we sought to compare the efficacy of VRP3014- and VRP3000-
based vaccines in young and aged animals with both lethal
homologous (SARS-CoV/influenza virus) and heterologous
(SARS-CoV) challenge. Importantly, aged animals that re-
ceived the VRP3000-based vaccines were completely protected
from influenza virus-induced morbidity and mortality, while
near-complete protection from homologous and heterologous
SARS-CoV challenge was achieved. Protection from mortality
in aged animals was coincident with the generation of neutral-
izing antibody. These data suggest that the specifications of the
VRP vaccine platform are key for the successful vaccination of
aged populations, who are more vulnerable to severe disease
caused by SARS-CoV and influenza virus. Future studies with
the VRP vaccine platform should provide further insight into
the mechanisms of successful protection in the elderly, and this
technology could be adapted to target other diseases that cause
disproportionate disease in the elderly, like West Nile virus,
norovirus, and other emerging viral diseases in the future.
MATERIALS AND METHODS
Viruses and cells. For the recombinant epidemic virus strain icSARS
(AY278741), rMA15, icGD03-S (AY525636), and rMA15 GD03-S, titers were
determined and viruses were propagated on Vero E6 cells as described elsewhere
(68). Vero E6 cells were grown in minimal essential medium (Invitrogen, Carls-
bad, CA) supplemented with 10% FCII (HyClone, South Logan, UT) and gen-
tamicin-kanamycin (UNC Tissue Culture Facility). All SARS-CoV virus work
was performed in a class II biological safety cabinet in a certified biosafety level
3 laboratory containing redundant exhaust fans, with laboratory personnel wear-
ing Tyvek suits and powered air-purifying respirators as described previously
(69). Recombinant influenza virus PR8 strain stock was kindly donated by Peter
Palese at Mt. Sinai Medical Center in New York City. All influenza virus work
was performed in a class II biological safety cabinet in a biosafety level 2
laboratory.
Construction of rMA15 GD03-S. rMA15 differs from the epidemic strain
SARS Urbani by 6 amino acids (H133Y nsp5, E269A nsp5, T67A nsp9, A4V
nsp13, Y436H Spike, and E11K M). Recently, we introduced the GD03-S gly-
coprotein into the SARS Urbani infectious clone, which resulted in the creation
of a recombinant chimeric SARS-CoV bearing a GD03-S, but this virus did not
produce lethal disease or cause significant weight loss in young or aged animals
(15, 53). To construct a recombinant mouse-adapted SARS-CoV bearing the
most divergent human SARS-CoV spike (S) glycoprotein, we inserted the GD03
spike gene (GenBank accession no. AY525636) into our infectious cDNA clone
of mouse-adapted SARS-CoV (rMA15) while retaining the mouse-adapting S
mutation Y436H (49). The SARS-CoV infectious cDNA clone was split among
six plasmids (A to F), and the S gene was split among the E and F plasmid clones.
The Y436H mutation was introduced into the GD03-S sequence by using over-
lapping PCR. Briefly, the icSARS-GD03-E pSMART fragment DNA was am-
plified by PCR using Expand high-fidelity polymerase (Roche, Indianapolis, IN)
with the following primer sets: amplicon A (NcoIF, 5-TGTTTCTAAACCCAT
GGGTACACAG-3; MA15spkR, 5-GATACCTATATTTATAATTATGATT
ACCAG-3) and Amplicon B(XbaIR, 5-GGGCCCTCTAGAGATCGAGC-3;
MA15spkF, 5-CTGGTAATCATAATTATAAATATAGGTATC-3). The final
overlap amplicon was purified using a Qiagen (Valencia, CA) PCR purification
kit and digested with NcoI and XbaI (New England BioLabs [NEB], Ipswich,
MA) for 1 h at 37°C. The target vector, icSARS GD03-E pSMART, was digested
similarly. The digested overlap amplicon (2.2 kb) and vector fragments (5.3 kb)
were gel purified using a QIAquick gel purification kit (Qiagen), ligated to create
rMA15 GD03-E pSMART, and sequence verified. To generate rMA15 GD03-F
pSMART, the 5 end of the GD03 spike contained in the icSARS GD03-F
plasmid was shuttled into the rMA15 F TOPO-XL plasmid. icSARS GD03
F pSMART was digested with BamHI (NEB), while rMA15-F TOPO-XL was
digested with BamHI and CIP (NEB). icSARS-GD03-F pSMART (2,059 bp)
and rMA15-F TOPO-XL (7,260 bp) fragments were gel purified and ligated to
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create rMA15 GD03-F TOPO-XL. Full-length rMA15 GD03-S cDNA was con-
structed, and in vitro transcripts were generated and electroporated into Vero E6
cells to create recombinant virus as described elsewhere (68). The rMA15
GD03-S virus from electroporation was passaged until cytopathic effect (CPE)
was seen (two passages) and plaque purified, and plaques were expanded on
Vero E6 cells to create a working virus stock, which was stored at 80°C until
use. Viral RNA from the rMA15 GD03-S virus stock was isolated using TRIzol
(Invitrogen), cDNA was synthesized using SuperScript II (Invitrogen), and re-
gions spanning the S, 3a, E, and M genes were PCR amplified and directly
sequenced. All GD03-S mutations and the Y436H mutation were present, but
one additional coding change was found outside the receptor binding domain of
S at residue 623, resulting in a change from serine to tyrosine.
The nucleotide sequences for the SARS variants used in this study have the
following GenBank accession numbers: SARS-CoV Urbani, AY278741; SZ16,
AY304488; GD03, AY525636). The influenza virus PR8 (A/Puerto Rico/8/34)
genes are catalogued as follows: PB2, GI 60484; PB1, GI 324897; PA, GI 60808;
HA, GI 62290; NP, GI 324709; NA, GI 324507; M, GI 60788; NS, GI 324833.
Virus growth curve analysis. Vero E6 cells were infected with icSARS,
icGD03-S, rMA15, or rMA15 GD03-S at a multiplicity of infection (MOI) of 0.01
for 1 h at 37°C, after which the inoculum was removed, the monolayer was rinsed
with Dulbecco’s phosphate-buffered saline (DPBS), and growth medium was
added. Medium was sampled at 0, 6, 12, 24, and 36 h postinfection (hpi), and
samples were stored at 80°C until titers were determined by plaque assay in
Vero E6 cells as described elsewhere (68).
Infection of young and aged BALB/c mice with SARS-CoV. Animal housing
and care were in accordance with all University of North Carolina Institutional
Animal Care and Use Committee guidelines. All BALB/c mice were purchased
from Harlan Sprague Dawley (Indianapolis, IN). Ketamine-anesthetized 10-
week-old (n 10/virus) or 12-month-old (n 6/virus) female BALB/c mice were
intranasally infected with 105 PFU of rMA15 or rMA15 GD03-S in 50 l, after
which clinical signs of disease (body weight) were monitored every day postin-
fection. At 2 and 4 days postinfection (dpi), groups of animals were sacrificed and
lungs were removed for histology and virus lung titer determinations using the
methods described below.
Lethal SARS-CoV challenge of aged BALB/c mice vaccinated with traditional
VRP-expressing Urbani S, GD03-S, SZ16-S, a pool of all three S-expressing
VRPs, or influenza virus HA. Twelve-month-old female Harlan Sprague Dawley
BALB/c mice (Indianapolis, IN) were vaccinated with 105 infectious units
(IU)/10 l of either influenza virus hemagglutinin (HA) glycoprotein, SARS-S,
GD03-S, SZ16-S VRP, or a pool of SARS S containing VRPs (pool-S; 105
IU/antigen) in the left rear footpad. The SARS-CoV strain GD03 was isolated
from a patient in the Guangdong region in China during the reemergence of
2003–2004, and it clusters with zoonotic viruses that were isolated from civets in
live animal markets during those outbreaks (15, 28, 53, 55, 56). SARS-CoV SZ16
was isolated from a Himlayan palm civet, and its S protein differs from the
epidemic strain, SARS-CoV Urbani, in 18 amino acids (13, 28, 55, 56). All VRPs
were “packaged” with VEE3014 strain glycoproteins (7, 14, 47). VRP IU titers
were generated through infection of baby hamster kidney (BHK) cells as de-
scribed elsewhere (22). Three weeks after primary vaccination (“prime”), ani-
mals were bled to assess SARS S-specific serum IgG. At 13 months of age, mice
received a secondary vaccination (“boost”) of the same dose and identity of their
primary vaccination. At 15 months of age, mice were bled to assess postboost
SARS-CoV-S-specific serum IgG and neutralizing antibody. A week later, mice
were intranasally infected with 105 PFU/50 l rMA15 GD03-S. Mice were mon-
itored daily for clinical signs (weight) and mortality. At 2 dpi, when SARS-CoV
lung titers are maximal, three animals per group were sacrificed to assess virus
lung titer and histology as described below. In an additional experiment, 12-
month-old female BALB/c mice were vaccinated with 106 IU of VRP Urbani-S
in a similar prime/boost regimen as described above. Prior to challenge, sera
were taken to measure the antigen-specific IgG response. At 17 months of age,
animals were intranasally infected with 105 PFU/50 l rMA15-GD03-S, after
which morbidity and mortality were monitored.
Vaccination and lethal SARS-CoV challenge of young adult and aged BALB/c
mice with VRPs packaged with wild-type VEE 3000 strain or traditional 3014
strain glycoproteins. Young adult and aged BALB/c mice were vaccinated with
VRPs expressing SARS-CoV GD03-S antigen packaged with either VRP3000 or
VRP3014 glycoproteins. Young adult and aged mice were vaccinated and boosted
with 105 IU of VRP3000 GD03-S or VRP3014 GD03-S. Young adult mice
(VRP3000 GD03-S, n  15; VRP3014 GD03-S, n  18) received their primary
vaccination at 8 weeks of age and were boosted at 11 weeks of age. Aged mice
(VRP3000 GD03-S, n  16; VRP3014 GD03-S, n  14) received their primary
vaccination at 12 months of age and were boosted at 13 months of age. All mice
were bled 2 weeks post-prime/boost in order to assess antigen-specific immune
responses by an enzyme-linked immunosorbent assay (ELISA) and neutraliza-
tion assay. At 14 weeks of age, young adult mice groups were each divided in half,
with one half receiving intranasal homologous challenge (105 PFU rMA15
GD03-S) and the other half receiving a heterologous challenge (105 PFU
rMA15). Groups of aged mice were divided into half and challenged similarly to
the young groups as described above. After challenge, mice were monitored daily
for morbidity (weight) and mortality. At 2 dpi, three mice in each group were
sacrificed and lungs were harvested for virus titer determinations and pathology
as described below. In the experiments above, equivalent PFU of VRP3000 and
VRP3014 were delivered. In an additional experiment to assess the magnitude of
the SARS-S-specific immune responses in young and aged animals after vacci-
nation with equivalent genomes of VRP3000 and VRP3014, 1.4  106 genomes of
either VRP3000 GD03-S or VRP3014 GD03-S were administered in a prime/boost
regimen in BALB/c mice similar in age and sex to those above (n  6 to 7
mice/group).
Vaccination and lethal influenza virus challenge of young adult and aged
BALB/c mice with VRPs packaged with wild-type VEE 3000 strain or traditional
3014 strain glycoproteins. Similar to the SARS-CoV experiment described
above, VPR vaccines expressing the chief influenza virus protective antigen, HA
(strain PR8), were generated with either VEE 3000 or VEE 3014 coat proteins.
Young adult and aged mice were vaccinated and boosted with 105 IU of VRP3000
HA or VRP3014 HA. Young adult mice (VRP3000 HA, n  9; VRP3014 HA, n 
9) received their primary vaccination at 8 weeks of age and were boosted at 11
weeks of age. Aged mice (VRP3000 HA, n  7; VRP3014 HA, n  9) received
their primary vaccination at 12 months of age and were boosted at 13 months of
age. To assess antigen-specific immune responses prior to challenge, serum from
all mice was collected 2 weeks post-prime/boost and analyzed by ELISA and
hemagglutination inhibition assay. At 14 weeks (young adult) and 15 months
(aged), mice were challenged with 500 PFU (10 50% lethal doses) of influenza
virus PR8. To demonstrate the pathogenesis of PR8 in unvaccinated young and
aged mice, we infected age-matched (14 weeks or 12 to 15 months) and sex-
matched unvaccinated BALB/c mice at the time of vaccine challenge. After virus
challenge, morbidity (weight) and mortality were monitored daily. On day 3 pi,
three mice in each group were sacrificed and lungs were harvested for virus titer
determinations and pathology as described below.
ELISA to assess SARS S-specific IgG in mouse sera. Antibodies directed
against SARS S antigen were quantitated in an ELISA as previously described (4,
15). Antigens for the ELISA were purchased (purified recombinant SARS Ur-
bani S proteins; BEI Resources, Manassas, VA) or generated through infection
of BHK cells with VRP GD03-S, VRP SZ16-S, or VRP HA. When using cell
lysates as antigen, a VRP expressing an irrelevant antigen in the ELISA was
included to control for background associated with VRP-specific antibodies in
vaccinated mice. Titers represent the serum dilution that corresponded to half
the maximum absorbance for each sample, measured at 450 nm. Comparisons
between half-maximal titers derived from different experimental groups were
statistically evaluated using the Mann-Whitney test, a nonparametric method.
Except for the “equivalent VRP genome” experiment described above, all sera
used in ELISAs were obtained from vaccinated animals that were subsequently
challenged.
Microneutralization and PRNT assays. For the microneutralization assay,
heat-inactivated serum was serially diluted in 2-fold increments beginning at
1:25, mixed with 100 PFU of rMA15 GD03-S, and incubated for 1 h at 37°C. The
combination of virus and serum was then added to a 96-well plate of Vero E6
cells (5  103 Vero E6 cells/well) in triplicate and incubated at 37°C until CPE
was assessed (4 to 5 dpi). For each dilution of serum, the number of wells
protected from CPE was scored. The greatest dilution of serum with more than
two wells of protection was considered the 50% neutralization titer (52). For the
plaque reduction neutralization (PRNT) assay, 100 PFU of rMA15 GD03-S was
incubated with 1:2 dilutions of heat-inactivated sera (final concentrations of
diluted sera ranged from 1:100 to 1:1,600) or medium (negative control) for 1 h
at 37°C. After the incubation, the serum-virus and medium-virus cocktails were
used as samples in a standard plaque assay. All serum samples were evaluated in
duplicate. The relative percentage of plaque reduction due to neutralization was
generated by comparing the average number of plaques per dilution of serum
and the number of plaques generated in the negative-control samples (virus plus
medium without serum). The dilution at which 50% of plaques were neutralized
was considered our PRNT50 value. All sera used in neutralization assays were
obtained from vaccinated animals that were subsequently challenged.
Hemagglutination inhibition assay. For the hemagglutination inhibition
(HAI) assay, a measurement of influenza virus HA-specific antibody responses
and a correlate of protection, 4 hemagglutinating units (HAU) of influenza virus
strain PR8 in 25 l were mixed with 2-fold serial dilutions of animal serum (25
l per dilution) and incubated at room temperature for 30 min. Fifty microliters
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of a 1% suspension of fresh chicken red blood cells (CRBCs) was then added to
each well. In wells with anti-HA antibody, virus was bound by antibody and was
not available to agglutinate the CRBCs. The maximal reciprocal serum dilution
where agglutination was completely inhibited is reported as the HAI value. All
sera used in the HAI assay were obtained from vaccinated animals that were
subsequently challenged.
Plaque assay to assess SARS-CoV lung titer. For determination of SARS-CoV
lung titers, briefly, portions of the lungs were weighed, placed in 0.5 ml DPBS,
and frozen at 80°C until analyzed. Lungs were then homogenized in a Mag-
nalyzer (Roche) and clarified by centrifugation (12,000 rpm; 1 min in a micro-
centrifuge), and virus titers within lung supernatants were assessed via plaque
assay in Vero E6 cells as described elsewhere (56).
TCID50 determinations to assess influenza virus lung titer. To quantitate the
amount of virus replication in naïve and vaccinated animals infected with the
lethal influenza virus strain PR8, we performed a 50% tissue culture infected
dose (TCID50) assay on clarified mouse lung homogenates according to methods
previously described (48). At 24 h prior to the start of the assay, Madin-Darby
canine kidney (MDCK) cells were plated in 96-well plates at a density of 105
cells/well. Twofold dilutions of clarified lung homogenates (see above) were
added in duplicate to 96-well plates of MDCK cells and incubated at 37°C for 1 h,
after which wells were rinsed and cell culture medium was added. As a positive
assay control, the titer of a previously characterized PR8 stock was also assessed.
After 3 days, cell culture medium was removed and plates were stained with a
vital crystal violet stain. The TCID50 titer/g was calculated as previously de-
scribed (48).
Lung histology. Lungs were fixed in 4% paraformaldehyde (PFA), paraffin
embedded, sectioned, and stained with hematoxylin and eosin (H&E). Sections
were evaluated and scored blindly by a trained pathologist (W. Funkhouser) for
levels of inflammation and lung tissue damage.
Statistical analysis. Statistical analysis was performed using the Prism soft-
ware (GraphPad, San Diego, CA). Nonparametric Mann-Whitney tests were
performed to generate the P values noted below in the text and figures.
Ethics statement. Experimental animal protocols were reviewed and approved
by the Institutional Animal Care and Use Committee at UNC Chapel Hill
according to guidelines set by the Association for the Assessment and Accredi-
tation of Laboratory Animal Care (AAALAC) and the United States Depart-
ment of Agriculture (USDA).
RESULTS
rMA15 GD03-S, rMA15, and epidemic SARS-CoV grow to
similar peak titers in vitro. Compared to the epidemic strain,
SARS Urbani, the mouse-adapted strain MA15 contains six
amino acid changes, one of which resides within the spike gene
(Fig. 1D). To mimic vaccine challenge by a newly emerged
pathogenic SARS-CoV strain, we constructed a recombinant
mouse-adapted SARS-CoV (rMA15-GD03-S) within the
MA15 background bearing a modified S of the most divergent
human strain, GD03 (i.e., native GD03-S, including the Y436H
mouse-adapting mutation) (15, 28, 53, 55). The GD03 S gly-
coprotein differed from Urbani by 17 amino acids (Fig. 1D),
and cross-neutralization of GD03 using antisera directed
against Urbani-S was reduced 10- to 15-fold (15). One amino
acid change relative to the cloned sequence (S623Y) was found
FIG. 1. In vitro and in vivo characterizations of rMA15 GD03-S. (A) Vero E6 cells were infected at an MOI of 0.01 with rMA15, icSARS, or
rMA15 GD03-S for 1 h at 37°C, after which monolayers were rinsed with DPBS and growth medium was added. At various times postinfection,
cell medium was sampled and frozen at 80°C until titers were determined by plaque assay in Vero E6 cells. (B) Ketamine-anesthetized
10-week-old (n  10 animals/virus) or 12-month-old (n  6 animals/virus) female BALB/c mice were infected with 105PFU/50 l of rMA15 or
rMA15 GD03-S, after which clinical signs of disease (weight loss) and mortality were monitored every day postinfection. Animals at or below 80%
of the starting weight were sacrificed based on the IACUC protocol. On days 2 and 4 postinfection, groups of animals were sacrificed and lungs
were removed for histology and virus lung titer determinations. Error bars represent 1 standard deviation. (C) Virus titers in the lungs of mice were
measured by standard plaque assay in Vero E6 cells. Error bars represent 1 standard deviation. (D) Schematic of S amino acid changes comparing
Urbani, GD03, MA15, and MA15 GD03-S.
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in the rMA15 GD03-S spike gene, possibly resulting from
passage in culture while generating the virus stock. Interest-
ingly, the recombinant icSARS GD03-S virus described by
Deming et al. developed a mutation (D613G) in a similar
region of S during the process of virus stock generation, sug-
gesting that some unique selective advantage for growth in
culture may be encoded within this undefined region of S (15).
To assess virus growth kinetics in vitro, Vero E6 cells were
infected with rMA15, rMA15 GD03-S, icGD03-S, or icSARS
(recombinant epidemic strain) at an MOI of 0.01. At 12 hpi,
rMA15, rMA15 GD03-S, and icSARS titers were 1 log higher
than that of icGD03-S. Although icGD03-S and rMA15
GD03-S growth seemed to be depressed at 24 hpi, all viruses
eventually achieved similar peak titers (108 PFU/ml) at 36
hpi (Fig. 1A).
Age is a critical factor in development of ARDS in BALB/c
mice infected with rMA15 GD03-S. Since the pathogenesis of
MA15 had not yet been evaluated in aged mice, we evaluated
the in vivo growth kinetics and pathogenesis of the novel
rMA15 GD03-S and parent rMA15. Upon infection of 10-
week-old BALB/c mice with 105 PFU of rMA15 GD03-S or
rMA15, all rMA15 GD03-S-infected mice lost approximately
10% of their body weight but survived, while rMA15-infected
mice rapidly lost 20% of their starting weight and uniformly
succumbed to infection by 5 dpi (Fig. 1B). Interestingly, virus
titers for rMA15 and rMA15 GD03-S were similar at both 2
dpi (rMA15, 3.2  107 PFU/g; rMA15 GD03-S, 1.5  107
PFU/g) and 4 dpi (rMA15, 3.6  105 PFU/g; rMA15 GD03-S,
9.3  105 PFU/g) (Fig. 1C). Unlike infection of young adult
mice, infection of aged mice with rMA15 or rMA15 GD03 was
uniformly lethal, causing rapid weight loss (20% starting
weight) and 100% mortality by 3 to 4 dpi (Fig. 1B).
To determine the severity and potential age-related differ-
ences in lung pathology, H&E-stained lung sections from
mock-infected and SARS-CoV-infected mice (2 and 4 dpi)
were blindly evaluated (Fig. 2). Compared to mock-infected
animals at 2 dpi, young and aged animals infected with rMA15
or rMA15 GD03 experienced a denuding bronchiolitis with an
accumulation of apoptotic debris within the airways and lym-
phocytic perivascular cuffing that was more severe in the aged.
In contrast to young infected mice, the hallmarks of diffuse
alveolar damage (DAD) and ARDS (i.e., hyaline membranes
in the alveoli [Fig. 2, double-headed arrow]) were readily ob-
served at 4 dpi in aged infected mice, suggesting that death was
likely due to DAD/ARDS-mediated respiratory failure. These
data demonstrate that rMA15 and rMA15 GD03-S infection
causes age-related severe end-stage lung pathogenesis
(ARDS) similar to what has been observed in the most severe
human cases.
Vaccination of aged mice with traditional VRP expressing
either Urbani-S, GD03-S, SZ16-S, or a cocktail of all three
VRP-S vaccines does not enhance protection from morbidity
or mortality. Since Deming et al. demonstrated that traditional
VRP3014 vaccines fail in aged mice upon heterologous chal-
lenge in a replication model, we sought to investigate the
efficacy of VRP3014 vaccines in aged mice through lethal
SARS-CoV heterologous challenge (15). Moreover, we hy-
pothesized that vaccination with a pool of divergent SARS-
CoV S antigens would increase the breadth of the immune
response in aged animals, providing increased protection from
a lethal heterologous challenge compared to animals receiving
a monovalent vaccination. To test this hypothesis we vacci-
nated 12-month-old female BALB/c mice in a prime/boost
regimen with traditional VRP3014-expressing SARS Urbani-S
(epidemic strain), GD03-S (the most divergent human strain),
SZ16-S (civet strain), a pool of all three SARS-CoV S antigens
(pool-S), or a control VRP expressing the influenza virus HA
glycoprotein. At 15 months of age, mice were intranasally
challenged with 105 PFU of rMA15 GD03-S, after which mor-
bidity and mortality were monitored daily. All groups exhibited
significant morbidity (20% loss of starting weight by 4 dpi)
and mortality (70 to 100%) after rMA15 GD03-S infection
(Fig. 3A). The groups receiving the VRP3014-expressing Ur-
bani-S, GD03-S, or pool-S demonstrated various degrees of
survival, while 100% of VRP3014 HA-vaccinated and VRP3014
SZ16-S-vaccinated mice died (Fig. 3A). Groups receiving the
homologous antigen (GD03-S or pool-S) demonstrated similar
levels of protection, suggesting that the other pool-S antigens
did not provide an additional protective benefit. Virus lung
titers were similarly high at 2 dpi (108 PFU mean lung titer)
in all vaccine groups (Fig. 3B). To determine the degree of
lung pathology at 2 dpi, H&E-stained lung sections were eval-
uated blindly (Fig. 3E). Peribronchivascular cuffing by lympho-
cytes and neutrophils was evident in all groups at low magni-
fication (40). Denuding bronchiolitis, focal apoptosis of the
airway epithelium, and blockage of the airway with apoptotic
debris were evident in GD03-vaccinated and pool-S-vaccinated
animals, but these manifestations of disease were more prom-
inent in Urbani-, SZ16-, and HA-vaccinated animals. Although
virus titer data at 2 dpi were similar for all groups, the pathol-
ogy and morbidity/mortality data suggest that animals receiv-
ing the GD03-S antigen (GD03-S or pool-S) experienced at
best a very low level of protection from the most severe disease
seen in the other groups. Importantly, increasing the dose of
VRP3014 Urbani-S to 10
6 IU in a prime/boost regimen did not
improve morbidity (weight nadir at 4 dpi, 85%	 9%) (mean	
standard deviation) or mortality (50%) to a level of complete
protection in aged mice following heterologous lethal chal-
lenge with rMA15 GD03-S, suggesting that even 10-fold more
VRP3014 could not enhance protection of aged mice (data not
shown).
Vaccination with a cocktail of divergent S-expressing VRPs
does not enhance the quality or breadth of the immune re-
sponse in aged mice. The development of an adequate neu-
tralizing antibody response against the SARS S glycoprotein
through vaccination is necessary to prevent SARS-CoV repli-
cation after challenge. We performed an ELISA with post-
boost sera and varied the target antigen in order to gauge
cross-reactivity of the immune response (Fig. 3C). When com-
paring peak IgG titers in each vaccine group expressing single
S variants, the titer of the greatest magnitude was typically
against the cognate vaccine antigen (Fig. 3C). Not surprisingly,
the mean log10 half-maximal IgG responses within the pool-S
group were similar for each antigen in the cocktail, with max-
imal IgG S responses to each S equivalent to those generated
from the single-S-vaccinated groups (Fig. 3C). Importantly,
sera from control VRP HA animals did not significantly cross-
react with the SARS antigens, and the magnitudes of HA-
specific responses were comparable to those seen in the SARS
S groups (Fig. 3C). Although the degree of mortality varied
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slightly between groups, the magnitudes of the mean log10
half-maximal GD03-specific IgG titers in each group were sim-
ilar (Fig. 3C). Importantly, animals receiving 106 IU VRP3014
Urbani-S had significantly elevated half-maximal IgG titers
(mean half-maximal Urbani IgG titer, 3.067 	 0.258; P 
0.0020) compared to animals that received 105 IU, but this
immune response was not robust enough to prevent morbidity
or mortality (data not shown). We performed a microneutral-
ization assay with rMA15 GD03-S to generate 50% neutral-
ization titers from postboost sera for each animal in the study
(Fig. 3D). One animal in the SZ16 group and one animal in the
GD03 group had a reciprocal 50% neutralization titer of 25,
while all other animals tested had titers below the limit of
detection. These data demonstrate (i) the inclusion of various
S antigens or a pool of S antigens does not increase the mag-
nitude of IgG cross-reactivity in aged animals with this vaccine
FIG. 2. rMA15 and rMA15 GD03-S infection induces ARDS in aged mice. Lung pathology of mock-infected and SARS-CoV-infected mice (2
and 4 dpi) was determined through blind scoring of H&E-stained lung sections. Compared to mock-infected animals, young animals infected with
rMA15 or rMA15 GD03 experienced a denuding bronchiolitis with an accumulation of apoptotic debris within the airways (solid arrow) and
perivascular cuffing caused predominately by lymphocytes (open arrowhead). Virus-induced lung pathology in the airways of aged mice was similar
to that in young mice (filled arrowhead), while the peribronchivascular cuffing associated with infiltrating immune cells (open-headed arrow) was
increased and readily visible at low power (dense purple areas; 40). In contrast to results at 2 dpi, damage to the conducting airway (apoptotic
debris in the airway, denuding bronchiolitis, etc.) was minimal and peribronchivascular cuffing (open arrowhead) was less severe at 4 dpi in both
young and aged mice. Most importantly, hyaline membranes (double-headed arrow), a sign of diffuse alveolar damage and ARDS, were observed
in many alveoli in aged animals infected with rMA15 or rMA15 GD03-S. These data suggest that the development of end-stage lung disease
(ARDS) in SARS-infected animals is age related and that aged animals most likely die from ARDS, while the cause of death in young animals
remains unknown. Vascular, alveolar, and bronchiolar lumen are labeled as VL, AL, and BL, respectively.
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FIG. 3. Morbidity and mortality was seen in all experimental groups of VRP3014-vaccinated 15-month-old rMA15 GD03-S-challenged BALB/c
mice. Twelve-month-old Harlan Sprague Dawley mice (Indianapolis, IN) were vaccinated in a prime/boost regimen with 105 IU/10 l of either
VRP3014 HA, SARS-S, GD03-S, SZ16-S VRP, or a pool of SARS S containing VRPs (pool-S) in the left rear footpad. At 15 months of age, mice
were infected with 105 PFU/50 l rMA15 GD03-S. (A) Morbidity (weight loss) and mortality were monitored daily. Error bars represent 1 standard
deviation. (B) Virus lung titers were assessed through standard plaque assay of clarified lung homogenates in Vero E6 cells, and average virus lung
titers were similar in all vaccinated groups at 2 dpi. Error bars represent 1 standard deviation. (C) The antigen-specific IgG response was measured
in postboost sera in triplicate by ELISA for each animal in which the Urbani-S, GD03-S, SZ16-S, or HA ELISA target antigen was employed,
allowing for the assessment of cross-reactivity. Error bars represent 1 standard deviation. (D) The percent neutralization for postboost sera was
determined in a microneutralization assay. Serum was serially diluted in 2-fold increments beginning at 1:25 and then mixed with 100 PFU of
rMA15 GD03-S and incubated for 1 h at 37°C. Virus and sera was then added to a 96-well plate of Vero E6 cells (5  103 Vero E6 cells/well) in
triplicate, and the development of CPE was scored 4 to 5 dpi. The greatest dilution of serum with more than two wells of protection was reported
as the 50% neutralization titer. (E) Lung pathology at 2 dpi was determined through the blind scoring of H&E-stained lung sections. Peribron-
chivascular cuffing was evident in all groups at low magnification (40). At high power, cuffing (opn arrowhead) was caused predominately by
lymphocytes and neutrophils. Denuding bronchiolitis, focal apoptosis of the airway epithelium (filled arrowhead), and blockage of the airway with
apoptotic debris (filled arrowhead) were evident in GD03- and pool-vaccinated animals, and these manifestations of disease were more prominent
in Urbani-, SZ16-, and HA-vaccinated animals. Vascular and bronchiolar lumen are labeled as VL and BL, respectively.
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platform, (ii) VRP vaccination of aged mice with single S
antigens or a pool of S antigens induces a robust antigen-
specific IgG response, but the neutralizing antibody response is
poor, leading to morbidity, mortality, and vaccine failure, and
(iii) increasing the dose of VRP expressing Urbani-S to 106 IU
in a prime/boost regimen significantly increased the antigen-
specific serum IgG responses in aged animals compared to
those receiving 105 IU, but this provided only partial protec-
tion from lethal heterologous challenge-induced morbidity and
mortality.
Wild-type VRP vaccines protect both young and aged ani-
mals from lethal homologous and heterologous SARS-CoV
challenge. Since VRP3014 vaccines failed to protect aged mice
from virus-induced morbidity and mortality from a heterolo-
gous challenge, we hypothesized that (i) the aged immune
system is incapable of developing a protective immune re-
sponse through vaccination, and/or (ii) innate factors in the
VRP3014 vaccine platform were contributing to vaccine failure
in the aged.
To determine if VRP-dependent factors were influencing
vaccine efficacy in the aged, we compared two different VRP
vaccine platforms (VRP3014 and VRP3000) in young and aged
animals through lethal homologous/heterologous SARS-CoV
challenge. VEE strain 3000 (wild-type) glycoproteins have
been demonstrated to specifically target dendritic cells in vivo,
and infection of mice with wild-type VEE 3000 is uniformly
lethal (38). VEE strain 3014 glycoproteins contain three amino
acid changes (E2, with E209K and I239N, and E1, with A272T)
that completely attenuate VEE-induced mortality in mice, due
at least in part to mutations that facilitate binding to heparan
sulfate (E209K), altering in vivo cell tropism (7). Young (8
weeks) and aged (12 month) BALB/c mice were vaccinated in
a prime/boost regimen with VRP3014 or VRP3000 expressing
SARS-CoV GD03-S and were subsequently challenged with a
lethal dose of rMA15 (heterologous) or rMA15 GD03-S (ho-
mologous). Upon challenge, young mice and aged mice were
14 weeks and 15 months old, respectively. In young adult mice,
the VRP3000 GD03-S vaccine provided complete protection
from morbidity, mortality, and virus replication (2 dpi) from
both homologous and heterologous challenges, while the
VRP3014 GD03-S-vaccinated groups experienced morbidity
(mean percent weight loss nadir, 8% on 3 dpi), limited mor-
tality (survival, 83%), and virus replication (Fig. 4A and B).
Consistent with earlier experiments, VRP3014 GD03-S again
failed to prevent morbidity and mortality in aged mice after
heterologous challenge, but almost all VRP3000-vaccinated
mice were completely protected from clinical disease (Fig. 4A).
While the VRP3000-based vaccines failed to prevent virus rep-
lication upon challenge in aged mice, significant differences in
virus lung titers were observed in comparison to VRP3014 (Fig.
4B). To assess lung pathology and inflammation postchallenge,
H&E-stained lung sections from 2 dpi were blindly evaluated.
Stark differences in lung pathology were seen when comparing
sections from aged animals vaccinated with VRP3000 versus
VRP3014 GD03-S (Fig. 5). In VRP3000 GD03-S-vaccinated and
rMA15 GD03-S-challenged animals, the airway epithelium ap-
peared normal and only minor peribronchivascular cuffing by
lymphocytes was observed. Similarly, VRP3000 GD03-S vacci-
nated animals heterologously challenged with rMA15 dis-
played normal airway epithelium but moderate cuffing of air-
ways and vasculature. In contrast, inflammation and damage to
the airways were visible at low power in VRP3014 GD03-S-
FIG. 4. Aged mice vaccinated with a wild-type VRP3000 vaccine expressing GD03-S are protected from SARS-CoV-induced mortality by both
homologous and heterologous challenge. (A) Morbidity and mortality of young and aged animals vaccinated with VRP bearing the VEE 3014 or
VEE 3000 glycoproteins expressing GD03-S in a prime/boost regimen and challenged with either rMA15 or rMA15 GD03-S. Error bars represent
1 standard deviation. (B) Virus titers were measured by plaque assay of clarified lung homogenates harvested at 2 dpi in Vero E6 cells. Significant
differences (P 0.05) between groups as judged by the Mann-Whitney test are marked with an asterisk. Error bars represent 1 standard deviation.
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vaccinated animals challenged with either rMA15 or rMA15
GD03-S, with denuding bronchiolitis, an accumulation of
apoptotic debris in the airway, and moderate lymphocytitic
prebronchivascular cuffing. The severe lung pathology seen in
naïve animals infected with rMA15 and rMA15-GD03-S (Fig.
2, DAD/ARDS) was not observed in vaccinated animals.
Wild-type VRP vaccines protect young and aged animals
from lethal homolgous influenza virus challenge. Since both
SARS-CoV and influenza virus cause more severe disease in
the aged, we broadened our scope to include influenza virus
vaccine/lethal challenge studies that were similar in design to
the SARS-CoV vaccine/challenge studies described above (5,
6). Young adult and aged mice were vaccinated with VRP3000
or VRP3014 expressing influenza virus HA in a prime/boost
regimen. Similar to SARS-CoV-vaccinated and challenged
young adult mice, VRP3000 HA vaccination was successful in
preventing morbidity, mortality, and virus replication from le-
thal influenza virus PR8 challenge (Fig. 6A and B). VRP3014
HA vaccination protected young mice from disease but not
from virus replication (Fig. 6A and B). Interestingly, the
VRP3000 HA was successful in preventing morbidity, mortality,
and PR8 virus replication in aged animals, while the VRP3014
HA vaccine provided only partial protection against disease
and none against virus replication (Fig. 6A and B). All naïve
young adult and unvaccinated aged mice uniformly succumbed
to infection by 7 dpi (Fig. 6A). To assess lung pathology in
vaccinated animals, H&E-stained lung sections from 3 dpi
were blindly evaluated. In naive (mock-infected) young or in
aged animals infected with influenza virus PR8, denuding
bronchiolitis, apoptosis of airway epithelial cells, and an accu-
mulation of apoptotic debris within the airway were observed,
while peribronchivascular cuffing by lymphocytes and neutro-
phils was visible at low magnification (40) (Fig. 7). Interest-
ingly, young animals vaccinated with VRP3014 HA presented
with similar pathology to naïve PR8-infected animals of the
same age, while virus-induced lung pathology was minimal in
the VRP3000 HA group. In aged HA-vaccinated animals, pa-
thology within the airway epithelium and peribronchivascular
cuffing were less severe than in young vaccinated animals, but
striking differences between the vaccine groups VRP3000 HA
and VRP3014 HA were not observed.
Antigen-specific serum IgG and neutralizing antibody re-
sponses are correlated with protection from disease and pre-
vention of virus replication upon SARS-CoV or influenza virus
challenge. Our previous experimentation suggested that
VRP3014-based vaccines can generate antigen-specific immune
responses in aged animals but fail to generate sufficient pro-
tective neutralizing antibodies. We hypothesized that vaccine-
specific factors or the aged immune system are responsible for
the failure to generate an adequate protective immune re-
sponse. To address this hypothesis, we performed several as-
says on postboost sera from young and aged VRP3000- and
VRP3014-vaccinated animals as described above in the chal-
lenge studies (ELISA to measure antigen-specific IgG, a
PRNT50 assay using rMA15 GD03-S to measure amounts of
SARS-CoV-neutralizing antibody, and an influenza virus HAI
assay, whose titers are a known correlate of protection) (2).
These data demonstrated that the aged immune system is quite
capable of generating antigen-specific IgG responses compa-
rable to those of young animals in groups receiving the
VRP3000-based vaccines (Fig. 8A). Moreover, groups that had
limited morbidity and mortality (VRP3000-vaccinated groups)
had significantly greater antigen-specific IgG responses than
groups that became ill (VRP3014-vaccinated groups), suggest-
ing that serum IgG responses correlate with protection from
disease (Fig. 8A). Furthermore, serum neutralizing antibody
titers in both VRP3000 GD03-S and HAI titers in HA-vacci-
nated groups were significantly higher than in the VRP3014
groups, demonstrating that the magnitudes of both neutraliz-
ing antibodies and HAI titers correlate with protection from
disease and death in the aged (Fig. 8B and C). In order to
ensure that the differences we had seen in the magnitude of the
immune responses through the delivery of equivalent PFU was
not due to the delivery of disparate numbers of total vaccine
particles, we vaccinated young and aged mice with equivalent
genomes of VRP3000 and VRP3014 expressing SARS-S. Similar
to what we had seen previously, the SARS-S-specific IgG
ELISA titers in VRP3000-vaccinated young and aged animals
FIG. 5. Aged mice are protected from severe SARS-CoV-induced
lung pathology through vaccination with variant VRPs. Lung pathol-
ogy in VRP-vaccinated aged mice was evaluated in H&E-stained lung
sections from 2 dpi in a blind manner. The airway epithelium appeared
normal, and only minor peribronchivascular cuffing by lymphocytes
was seen in animals receiving the V3000 GD03-S vaccine and homolo-
gously challenged with rMA15 GD03-S. Similarly, VRP3000 GD03-S-
vaccinated mice heterologously challenged with rMA15 displayed nor-
mal airway epithelium but moderate cuffing of airways and vasculature.
In contrast, inflammation and damage to the airways were visible at
low power in VRP3014 GD03-S-vaccinated animals challenged with
either rMA15 or rMA15 GD03-S. At high power (400), denuding
bronchiolitis, an accumulation of apoptotic debris in the airway (filled
arrowhead), and moderate lymphocytic prebronchivascular cuffing
(open arrowhead) was seen in VRP3014-vaccinated and challenged
animals.
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(young, 3.863 	 0.064; aged, 2.689 	 0.301) were significantly
greater in magnitude (aged VRP3000 versus aged VRP3014, P
0.0043; young VRP3000 versus young VRP3014, P  0.0022) to
those generated by VRP3014 vaccines (young, 2.106 	 1.432;
aged, 0.799 	 1.084) (data not shown). Taken together, these
data demonstrate that the aged immune system is capable of
generating a robust protective immune response, given the
appropriate stimulus, and VRP3000-based vaccines induce sig-
nificantly more robust immune responses in the young and
aged compared to VRP3014-based vaccines.
DISCUSSION
The dysregulation of the immune system with aging (i.e.,
immunosenescence) is in part responsible for the dispropor-
tionate rates of disease observed in the elderly infected with
SARS-CoV, influenza virus, or West Nile virus and decreased
efficacy of vaccination in the aged (1, 9, 25, 35, 43, 61). Fur-
thermore, human infection by SARS-CoV and recently
emerged influenza viruses (H5N1 and H1N1) can cause a most
severe respiratory condition, ARDS, whose development re-
sulting from SARS-CoV infection was a function of increasing
age (28, 40, 45, 70). The molecular mechanisms responsible for
age-related susceptibility to severe viral diseases and the po-
tential overlap with mechanisms of age-related vaccine failures
are not well understood. Surprisingly, very few small animal
models exist to simultaneously study disproportionate viral
disease in the aged and age-related defects for vaccine efficacy.
Roberts et al. elegantly developed a mouse-adapted SARS-
CoV (MA15) model through serial passage of SARS Urbani in
the lungs of young BALB/c mice, but its pathogenesis in aged
mice has not yet been reported (49). Using the novel rMA15
GD03-S SARS-CoV and its parent rMA15, we developed two
models of SARS-CoV pathogenesis that mimicked the age-
related severity of disease and age-related development of
ARDS seen in humans during the recent SARS epidemic.
Since young adult mice survive rMA15 GD03-S infection but
aged mice do not, these data suggest that the Y436H mouse-
adapting mutation, which was selected for function in the Ur-
bani backbone, loses its potency in the context of the GD03-S
structure. Importantly, the attenuating effects of GD03-S on
pathogenesis in young mice are likely cancelled by age-related
defects in the immune/pulmonary systems that contribute to
the increased pathogenesis. Although mouse lung titer data for
both rMA15 and rMA15 GD03-S were similar at the times
evaluated (2 and 4 dpi), the in vitro growth data suggested that
rMA15 may also hold a growth advantage prior to 2 dpi, likely
setting the course for lethal infection. Most importantly, unlike
young mice infected with rMA15, only rMA15-infected and
rMA15 GD03-S-infected aged mice developed signs of ARDS,
although all three infections were uniformly fatal. These data
suggest that age-related host factors contribute to the devel-
opment of ARDS and that the cause of death in young and
aged mice infected with rMA15 are likely different. Although
aged models of SARS-CoV pathogenesis and ARDS in
C57BL/6 strains have not yet been reported, we recently dem-
onstrated that rMA15 infection of young C57BL/6 mice results
in survival, suggesting that host genetics as well as age play an
integral role in the prevention or progression to ARDS (54).
Furthermore, recent studies by Frieman et al. suggest that a
host innate signaling protein, STAT1, contributes to the de-
velopment of ARDS in mice infected with SARS-CoV, solid-
ifying the hypothesis that both age and host factors contribute
FIG. 6. Aged mice vaccinated with a wild-type VRP3000 expressing influenza virus HA are protected from lethal influenza virus challenge.
(A) Morbidity and mortality of young and aged vaccinated or naïve mice were monitored after a lethal influenza virus PR8 infection (500 PFU).
Significant differences (P 0.05) between groups as judged by the Mann-Whitney test are marked with an asterisk. Error bars represent 1 standard
deviation. (B) Virus replication was measured in clarified lung homogenates in a TCID50 assay in MDCK cells. Error bars represent 1 standard
deviation.
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to the development of end-stage lung disease resulting from
virus infection (23). Interestingly, influenza virus strain A/PR8/
34, which was adapted for lethal disease in young mice, does
not produce more severe disease in aged animals, suggesting
that tightly balanced virus-host interactions likely contribute to
age-related disease. The development of small animal models
with age-related influenza disease severity might provide a
more relevant system for the evaluation of mechanisms of
influenza virus pathogenesis and vaccine efficacy. The data
from the rMA15/rMA15 GD03-S models suggest that (i)
1-year-old, aged animals are more susceptible to infection due
to immunosenescence, (ii) one or more protective host re-
sponses within young adult mice are absent in aged mice, or
that (iii) aged mice are less resilient in handling acute lung
damage. We also recognize that a complex interplay of all
three scenarios or yet-undiscovered scenarios could potentially
explain the enhanced mortality and development of ARDS
within aged animals as well.
Not only are effective multivalent platforms needed for vac-
cinating aged populations, but the choice of vaccine and anti-
gen design for controlling emerging and reemerging pathogens
further complicates an already difficult task due to the un-
known antigenic identity of future emergents. Because surveil-
lance and tracking of potential emerging viral diseases in wild
animal populations is difficult and time-consuming, our most
effective public health intervention may be to develop vaccine
platforms that induce broadly cross-reactive immunity in all
ages. Prior to this report, all SARS-CoV vaccine studies in
mice were performed within SARS-CoV replication models
for which modest viral loads were seen in the lung postinfec-
tion and overt signs of clinical disease were not observed (11,
15, 17, 18, 58, 67). Furthermore, vaccination and challenge of
young adult mice, whose immune system is uncompromised, is
not the most stringent evaluation of vaccine efficacy. Vaccine
studies of the aged, who are in part immunocompromised,
provide a much more stringent system to assess the robustness
and efficacies of vaccines (15). Like SARS-CoV, few studies of
influenza vaccine efficacy have been performed in aged mouse
models, even though seasonal influenza affects the aged most
severely. In 1993, Ben-Yehuda et al. demonstrated that a re-
combinant vaccinia virus vaccine expressing influenza virus
PR8 HA protected aged mice from intranasal challenge by a
homologous PR8 strain while conventional vaccines (killed
FIG. 7. Young and aged mice are protected from severe influenza
virus-induced lung pathology through VRP vaccination. Lung pathol-
ogy in naïve or VRP-vaccinated young and aged mice was evaluated in
H&E-stained lung sections harvested at 3 dpi in a blind manner. In
naive (mock) young or aged animals, denuding bronchiolitis, apoptosis
of airway epithelial cells, and an accumulation of apoptotic debris
within the airway was observed (filled arrowhead). Also, peribron-
chivascular cuffing (open arrowhead) visible at low power (40) was
observed, caused predominately by lymphocytes and neutrophils. In
young vaccinated animals, VRP3014 HA-vaccinated animals presented
with similar pathology to naïve PR8-infected animals, while virus-
induced lung pathology was minimal in all of the VRP3000 HA-vacci-
nated groups. In aged vaccinated animals, pathology within the airway
epithelium and peribronchivascular cuffing was less severe than in
young vaccinated animals. The pathology seen in aged naïve animals
was identical to that seen in young naïve animals.
FIG. 8. The successful generation of a neutralizing antibody re-
sponse in aged mice through VRP3000 vaccination correlates with pro-
tection from mortality. (A) Antigen-specific total IgG was measured in
triplicate in postboost sera of young and aged mice vaccinated with
VRP3000 GD03-S, V3014 GD03-S, VRP3000 HA, or VRP3014 HA.
(B) The neutralizing antibody response was measured in GD03-S-
vaccinated young and aged animals in a PRNT50 assay, in which we
report the serum dilution that reduced plaque numbers by 50%.
(C) Influenza virus HA-specific antibody levels, a known correlate of
protection, were measured in an HIA. Significant differences (P 
0.05) between groups as judged by the Mann-Whitney test are marked
with an asterisk. Error bars represent 1 standard deviation.
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virus vaccine) failed (6). Similarly, Asanuma et al. (3) demon-
strated partial protection of various strains (BALB/c, C57BL/6,
and C3H) of aged mice from PR8 challenge after conventional
vaccination (3). Since effective vaccination strategies in the
elderly have not yet been developed for norovirus, influenza
virus, West Nile virus, and SARS-CoV, the development of
small animal models of age-related viral pathogenesis to study
the efficacy of new vaccine platforms in aged populations could
have a broad public health application. With this report, we
demonstrate the effective VRP-based vaccination of aged pop-
ulations through the generation of a robust cross-reactive im-
mune response that facilitated protection from homologous
and heterologous lethal SARS-CoV challenge and homolo-
gous lethal influenza virus challenge. As immune functions
deteriorate with in aging, vaccine formulations that protect the
aged will almost certainly be extremely successful in younger
adults and may well be a universal paradigm regardless of
vaccine design.
VRP vaccines have recently been clinically proven to be safe,
replication-incompetent vaccine vectors capable of inducing
mucosal immunity from a peripheral route of inoculation (8,
37, 60). Our current study confirms and expands upon earlier
studies within SARS-CoV replication models in which the re-
sultant immune responses from VRP3014 SARS-S vaccination
in aged mice were insufficient to prevent heterologous chal-
lenge virus replication (15). Since the delivery of single
VRP3014-S, a pool of VRP3014-S, and even 10-fold more
VRP3014-S failed to provide protection from lethal disease
after heterologous challenge, we hypothesized that vaccine-
specific factors and/or immunosenescence might be responsi-
ble for the failure of VRP3014-based vaccines in the aged. To
test this hypothesis, we constructed variant VRP vaccines pack-
aged with either VEE strain 3014 glycoproteins, as used in
previous experiments (Deming et al. and other studies de-
scribed above) or wild-type VEE strain 3000 glycoproteins
(15). Using VRP3000-based vaccines, we demonstrated protec-
tion of the aged against two disparate respiratory viral infec-
tions that disproportionately affect the aged. The control of
virus replication and the limited morbidity/mortality in the
VRP3000 groups was coincident with the generation of a robust
neutralizing antibody response consistent with several reports
in which passive transfer of human monoclonal antibodies was
highly protective against both lethal homologous and heterol-
ogous SARS-CoV (51, 52). Although the delivery of a cocktail
of VRP3014-based vaccines failed to enhance cross-protection
and survival, it will be interesting to assess the potential en-
hancement of the immune response by cocktails of VRP3000-
based vaccines in protection from lethal heterologous SARS-
CoV strains. Furthermore, given the recent data of Wei et al.,
who reported a DNA prime/adenovirus 5 boost vaccine regi-
men enhanced cross-neutralization of divergent influenza virus
strains over the traditional influenza vaccine, it will be inter-
esting to see if the immune response generated by VRP3000-
based influenza vaccines will protect against heterologous in-
fluenza virus challenge (65). Future studies comparing
VRP3000 and VRP3014 may help elucidate novel molecular
immunologic defects related to immunosenescence and at the
least identify the immunologic signatures required for VRP-
mediated protection in the aged. Moreover, our data suggest
that VRP coats and/or dosages may need to be altered for use
in elderly populations in order to provide protection from
diseases that cause disproportionate disease in the aged.
Studies of VEE pathogenesis and recent VRP vaccine stud-
ies help explain the differences seen when comparing the im-
mune responses generated by VRP3000 and VRP3014. Data
from Bernard et al. and Macdonald et al. suggest that VEE3014
glycoproteins (amino acid changes from wild-type VEE3000, E2
with E209K and I239N and E1 with A272T) nonspecifically
bind heparan sulfate on the surface of cultured cells and the
natural in vivo cell targeting of dendritic cells is abrogated by
heparan sulfate-binding mutations (7, 38). In support of the
VEE studies discussed above, Fluet et al. demonstrated that
differential in vivo cell targeting by VRP3014 and VRP3000 sig-
nificantly affected both cellular and humoral responses, where
the VRP3000-based vaccines induced superior immune re-
sponses in young adult mice (22). It is important to note that in
comparing numbers of VRP genomes by real-time PCR and
VRP “infectious unit” titers for BHK cells, Fluet et al. re-
ported that VRP3000 is about 10- to 50-fold less infectious than
VRP3014 in vitro (22). In effect, the vaccination of mice with
similar numbers of infections units of VRP3000 or VRP3014
resulted in the delivery of approximately 10- to 50-fold more
genome copies with VRP3000 vaccines, but vaccination with
approximately 100-fold less VRP3000 resulted in an unchanged
immune response still superior to that of the VRP3014 variant
vaccine (22). Since an increased dose of VRP3000 vaccine did
not increase the magnitude of the immune response accord-
ingly, these data suggest that VRP3000 target cells in vivo are
limiting and saturated even with a 100-fold reduction in dose.
Similar to the findings of Fluet et al., we found that that
delivery of equivalent genomes of VRP3014 or VRP3014 vac-
cines expressing SARS-S resulted in a significantly more robust
immune response in VRP3000-vaccinated animals, and this dif-
ference was evident in young and aged animals (22). Moreover,
the delivery of 10-fold more IU of VRP3014 vaccine did not
protect aged animals from lethal SARS-CoV challenge. Taken
together, these results predict that repeated boosts with a
VRP3014-based vaccine would have minimal impact on improv-
ing immune responses in the aged due to altered in vivo tar-
geting but that repeated doses of VRP3000-based vaccines
would generate enhanced responses based on the cells targeted
and potential differences in the pathways of target cell antigen
presentation. Future studies comparing immune cell targeting
and dendritic cell activation and function as well as direct and
indirect antigen presentation in young and aged vaccinated
mice should help elucidate the molecular basis for VRP3000’s
superior immunogenic properties compared to VRP3014.
Effective vaccines directed against emerging pathogens
should induce the broadest possible immune response in order
to maximize the probability that the vaccine will protect against
future emergents from the zoonotic pool. Whenever possible,
homologous vaccine challenge models without morbidity or
mortality should be replaced by more stringent heterologous
lethal challenge models, in order to more accurately model
vaccine challenge by an emerging disease. Within our models
of age-related SARS-CoV pathogenesis and ARDS, we have
demonstrate the first effective vaccines in the aged that are
sufficient to protect against heterologous lethal SARS-CoV
challenge and lethal homologous influenza virus challenge. To
build upon the data we have obtained in young and aged
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mouse models, aged ferret and primate models should also be
developed to expand the numbers of models within which
scientists can study immunosenescence in the context of virus
infection and vaccination. Compared to young animals, aged
macaques display more severe disease pathology following
SARS-CoV infection, potentially providing a robust nonhu-
man primate model for vaccine testing in aged populations
(57). To our knowledge, similar models for influenza virus have
not been reported. Finally, to maximize the public health ben-
efits of vaccination, vaccine platform technologies should be
successful for all ages and especially in the most vulnerable
populations, like the elderly, who are often disproportionately
targeted by emerging viral diseases such as SARS-CoV, West
Nile virus, and influenza virus.
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